CervoMed Company Leadership
| CRVO Stock | 8.43 1.02 13.77% |
CervoMed employs about 15 people. The company is managed by 9 executives with a total tenure of roughly 35 years, averaging almost 3.0 years of service per executive, having 1.67 employees per reported executive. Analysis of CervoMed's management performance can provide insight into the firm performance.
CervoMed Management Team Effectiveness
The company has return on total asset (ROA) of (0.5619) % which means that it has lost $0.5619 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9342) %, meaning that it created substantial loss on money invested by shareholders. CervoMed's management efficiency ratios could be used to measure how well CervoMed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of July 2025, Return On Tangible Assets is likely to drop to -0.4. In addition to that, Return On Capital Employed is likely to drop to -0.49. At this time, CervoMed's Asset Turnover is very stable compared to the past year.As of the 22nd of July 2025, Common Stock Shares Outstanding is likely to grow to about 8.5 M, while Net Loss is likely to drop (5.5 M).
CervoMed Workforce Comparison
CervoMed is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 187,426. CervoMed adds roughly 15.0 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of (2.01) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.77) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.77. CervoMed Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CervoMed insiders, such as employees or executives, is commonly permitted as long as it does not rely on CervoMed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, CervoMed insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gregoire Sylvie over three weeks ago Acquisition by Gregoire Sylvie of 8100 shares of CervoMed at 6.52 subject to Rule 16b-3 | ||
Boger Joshua S over a month ago Acquisition by Boger Joshua S of 5750 shares of CervoMed at 19.01 subject to Rule 16b-3 | ||
Alam John J over three months ago Acquisition by Alam John J of 60000 shares of CervoMed at 2.3 subject to Rule 16b-3 | ||
Poulton Jeffrey V. over three months ago Acquisition by Poulton Jeffrey V. of 5750 shares of CervoMed at 19.01 subject to Rule 16b-3 | ||
Elder William Robert over six months ago Acquisition by Elder William Robert of 1000 shares of CervoMed at 18.16 subject to Rule 16b-3 | ||
Zavrl Frank over a year ago Acquisition by Zavrl Frank of 5750 shares of CervoMed at 19.01 subject to Rule 16b-3 | ||
Boger Joshua S over a year ago Disposition of 495995 shares by Boger Joshua S of CervoMed at 0.001 subject to Rule 16b-3 | ||
John Tanner over a year ago Acquisition by John Tanner of 16000 shares of CervoMed subject to Rule 16b-3 |
CervoMed Notable Stakeholders
A CervoMed stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CervoMed often face trade-offs trying to please all of them. CervoMed's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CervoMed's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| John MD | CEO, CoFounder | Profile | |
| Sylvie PharmD | CoFounder Director | Profile | |
| Dr Cobuzzi | Chief Officer | Profile | |
| Mark Rosch | Government Regulatory | Profile | |
| Claudia MD | Senior Science | Profile | |
| John Tanner | Chief Officer | Profile | |
| Marinus Verwijs | Executive Operations | Profile | |
| William JD | General Secretary | Profile | |
| Kelly MHA | Executive Development | Profile |
About CervoMed Management Performance
The success or failure of an entity such as CervoMed often depends on how effective the management is. CervoMed management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CervoMed management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CervoMed management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.46) | (0.49) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.42) | (0.44) |
CervoMed Workforce Analysis
Traditionally, organizations such as CervoMed use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CervoMed within its industry.CervoMed Manpower Efficiency
Return on CervoMed Manpower
| Revenue Per Employee | 649.2K | |
| Revenue Per Executive | 1.1M | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 1.8M | |
| Working Capital Per Employee | 2.6M | |
| Working Capital Per Executive | 4.4M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CervoMed. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in CervoMed Stock, please use our How to Invest in CervoMed guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CervoMed. If investors know CervoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CervoMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.17) | Revenue Per Share | Quarterly Revenue Growth (0.18) | Return On Assets | Return On Equity |
The market value of CervoMed is measured differently than its book value, which is the value of CervoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CervoMed's value that differs from its market value or its book value, called intrinsic value, which is CervoMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CervoMed's market value can be influenced by many factors that don't directly affect CervoMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CervoMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if CervoMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CervoMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.